Terumo Cardiovascular Systems Announces U.S. Distribution Agreement with Nonin
Medical for Nonin's EQUANOX™ 7600 Regional Oximetry System
ANN ARBOR, Mich., April 5, 2013
ANN ARBOR, Mich., April 5, 2013 /PRNewswire/ --Terumo Cardiovascular Systems
today announced that it has entered into a multi-year distribution agreement
with Nonin Medical, Inc., a leader in noninvasive medical monitoring.
Beginning May 1, 2013, Terumo CVS will distribute Nonin's EQUANOX™ Model 7600
Regional Oximetry System to adult and pediatric cardiovascular hospitals in
the United States; Nonin's direct sales force will focus on certain
non-cardiovascular applications in those hospitals, and applications in all
other U.S. hospitals. Terumo CVS manufactures and markets medical devices for
the global cardiac surgery market. Nonin Medical and Terumo CVS will make the
announcement at the Society of Cardiovascular Anesthesiologists (SCA) Annual
Meeting in Miami, Florida.
(Photo: http://photos.prnewswire.com/prnh/20130405/DE89304 )
The Nonin EQUANOX Model 7600 Regional Oximetry System is a noninvasive medical
monitoring system that continuously detects oxygen saturation status in the
brain and tissue beneath the sensor during surgical procedures and in
intensive care environments such as pediatric and neonatal intensive care
units. The system allows anesthesiologists, perfusionists, cardiovascular
surgeons, and other clinicians to quickly react to reverse tissue ischemia
events before they become critical.
"We are confident that Terumo's extensive cardiovascular relationships in
heart hospitals, combined with the clinical benefits and technology
advancements of the EQUANOX System, will drive further adoption of Nonin's
regional oximetry solution across the hospital as a cost-effective,
standard-of-care tool that helps prevent brain and organ injury in patients,"
said Chris Holland, Vice President of Business Development for Nonin Medical.
"Terumo CVS' new collaboration with Nonin Medical expands our patient
monitoring technologies to include state-of-the-art regional oximetry," said
Eric Sklar, Vice President - Business Development for Terumo CVS. "Unlike
other regional oximetry systems that may only indicate whether oxygen levels
are increasing or decreasing, EQUANOX system's patented technology provides
real-time absolute accuracy of actual physiologic conditions on neonatal to
adult patients, regardless of age, weight or skin color. We're pleased to be
able to offer this technology to new and current Terumo CVS customers, while
further reinforcing our global leadership in the cardiovascular market."
About 500,000 cardiovascular surgical procedures are performed annually in the
U.S. Regional oximetry-monitored procedures typically allow for early
indication of oxygen desaturation that could lead to stroke, neurocognitive
decline and other neurological or major organ injuries resulting from
inadequate oxygen saturation. Regional oximetry solutions have been shown to
reduce the cost of post-operative care and improve patient outcomes.^1
Advantages of the EQUANOX Advance Model 7600 Regional Oximetry System include:
oCerebral and Somatic Monitoring – Up to four channels displayed on one
screen for monitoring oxygen saturation in the brain and somatic sites on
oPatented Dual-Light Emitters and Dual Detectors with Four Wavelength
Accuracy – The first and only device that utilizes a dual-light emitting
and dual-detecting sensor architecture, which has been shown to more
effectively target the cerebral cortex, eliminating surface artifacts that
interfere with measurement accuracy.^2
oAbsolute Accuracy – Assures accurate measure of tissue saturation at a
point in time, not just relative or trending accuracy of changes.
oConsistency and Reliability – Rapid, reliable response to change without
signal instability and interruptions from electrical and ambient light
oPortability and Connectivity – Lightweight, durable monitor with long
battery life and pole-mounting capability for continually monitoring
patients during intra-hospital transport. Data output available via
Bluetooth^® wireless technology or RS232 connection.
For more information about the Nonin EQUANOX System, visit
About Terumo Cardiovascular Systems Corporation
Terumo Cardiovascular Systems Corporation manufactures and markets medical
devices for the global cardiac surgery market and is the U.S. distributor for
Vascutek^® Vascular Grafts. The company is headquartered in Ann Arbor,
Michigan, with manufacturing operations in Ann Arbor; Elkton, Maryland; and
Ashland, Massachusetts. It is one of several subsidiaries of Terumo
Corporation of Japan that is focused exclusively on cardiac and vascular
specialties, including Terumo Heart, Inc., developer of a ventricular assist
device and Vascutek, Ltd., manufacturer of a broad portfolio of vascular
grafts. For more information, visit www.terumo-cvs.com.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device
manufacturers with $5 billion in sales and operations in more than 160
nations. Founded in 1921, the company develops, manufactures, and distributes
world-class medical devices including products for use in cardiothoracic
surgery, interventional procedures, and transfusion medicine; the company also
manufactures a broad array of syringe and hypodermic needle products for
hospital and physician office use. Terumo contributes to society by providing
valued products and services to the healthcare market and by responding to the
needs of healthcare providers and the people they serve.
About Nonin Medical, leaders in noninvasive medical monitoring
Nonin Medical, Inc. invented the finger pulse oximeter and designs and
manufactures noninvasive medical monitoring solutions that meet customers'
technology needs today and tomorrow. Headquartered in Minneapolis, Minn., with
a customer center in Amsterdam, the Netherlands, Nonin Medical sells its pulse
and regional oximeters, capnographs, sensors and software to health
professionals and consumers in more than 125 countries. The company also has
more than 100 OEM partners worldwide. For more information, visit
^1 Goldman SM, Sutter FP, Wertan MA, et al. Outcome improvement and cost
reduction in an increasingly morbid cardiac surgery population. Semin
Cardiothorac Vasc Anesth 2006;10:171-5.
^2 Davie SN, Grocott HP. Impact of Extracranial Contamination on Regional
Cerebral Oxygen Saturation: A Comparison of Three Cerebral Oximetry
Technologies. Anesthesiology. 2012; 116(4):1-7.
©2013 Terumo Cardiovascular Systems Corporation. Terumo® is a trademark of
Terumo Corporation. EQUANOX™ is a trademark of Nonin Medical, Inc. Vascutek®
is a trademark of Vascutek Ltd. Bluetooth® is a trademark of Bluetooth SIG.
SOURCE Terumo Cardiovascular Systems
Contact: Melinda Yaklin, Director, Corporate Communications, Terumo
Cardiovascular Systems Corporation, Phone: +1 734 741 6068,
firstname.lastname@example.org, www.terumo-cvs.com; Melanie Stanek,
Director, Corporate Communications, Nonin Medical, Inc., Phone: +1 612 804
7714, email@example.com, www.noninequanox.com/news
Press spacebar to pause and continue. Press esc to stop.